Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839302 · ClinicalTrials.gov registry record
Detection and Delineation of Necrotizing Fasciitis Via a Vascular Perfusion Fluorophore
A clinical trial of Necrotising Fasciitis, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT04839302: Completed study of Necrotising Fasciitis, sponsored by Dartmouth-Hitchcock Medical Center.
NCT04839302 is a study of Necrotising Fasciitis that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839302, a study of Necrotising Fasciitis, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this work is to determine if fluorescence signal intensity changes from a vascular perfusion fluorophore (indocyanine green) can be associated with the presence of necrotizing fasciitis. Hypothesis - Tissue regions affected with necrotizing fasciitis will demonstrate reduced fluorescence intensity compared to an unaffected region without clinical evidence of necrotizing fasciitis.
Primary Outcome
Administration of ICG and subsequent imaging of a bodily region affected with NF will demonstrate substantially reduced fluorescence compared to the patient's unaffected tissues. Demonstration that ICG fluorescence voids are characteristic of NF.
Conditions Studied
Interventions
- DRUG Indocyanine green solution
Study Locations (1)
New Hampshire
- Dartmouth-Hitchock - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2024-12-04 |
What the finished NCT04839302 record still lists
NCT04839302 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 1 condition, with Necrotising Fasciitis appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine green solution is the first listed.
NCT04839302 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT04839302 about?
NCT04839302 is a clinical study titled "Detection and Delineation of Necrotizing Fasciitis Via a Vascular Perfusion Fluorophore". The primary objective of this work is to determine if fluorescence signal intensity changes from a vascular perfusion fluorophore (indocyanine green) can be associated with the presence of necrotizing fasciitis. Hypothesis - Tissue regions affected with necrotizing fasciitis will demonstrate reduce...
What is the current status of trial NCT04839302?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2021-04-05. Estimated completion is 2024-12-04.
What conditions does trial NCT04839302 study?
This clinical trial studies the following conditions: Necrotising Fasciitis.
What interventions are being tested in trial NCT04839302?
The interventions under investigation include: Indocyanine green solution (DRUG).
Who is sponsoring clinical trial NCT04839302?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04839302 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI